F-STAR THERAPEUTICS, INC. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2019-10-10: Study NCT04059198; Company role Lead sponsor; Phase Phase 2; Status Terminated.
- 2019-06-18: Study NCT04023721; Company role Lead sponsor; Phase Phase 2; Status Terminated.
- 2019-04-11: Study NCT03932513; Company role Lead sponsor; Phase Phase 2; Status Terminated.
- 2018-05-07: Study NCT03493698; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2019-10-10 | NCT04059198 Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus | Lead sponsor | Phase 2 | Terminated | Hepatitis B; HBV; Hepatitis B, Chronic | 5 | 2020-04-02 |
| 2019-06-18 | NCT04023721 Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor | Lead sponsor | Phase 2 | Terminated | Hepatitis B; HBV; Hepatitis B, Chronic | 64 | 2020-07-16 |
| 2019-04-11 | NCT03932513 Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients | Lead sponsor | Phase 2 | Terminated | HBV; Hepatitis B; Hepatitis B, Chronic | 8 | 2019-12-21 |
| 2018-05-07 | NCT03493698 A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects | Lead sponsor | Phase 1 | Completed Results posted | Drug Interaction Potentiation | 17 | 2018-08-27 |
| 2018-02-28 | NCT03434353 Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB) | Collaborator Lead: Gilead Sciences | Phase 2 | Terminated Results posted | Chronic Hepatitis B | 123 | 2021-01-26 |
| 2016-05 | NCT02751996 A Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic HBV | Lead sponsor | Phase 2 | Completed | Hepatitis B; Hepatitis, Viral | 80 | 2020-02-10 |
| 2013-03 | NCT01803308 A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection | Collaborator Lead: Syneos Health | Phase 1 | Completed | Hepatitis C Infection | 37 | 2014-08 |